Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Delivery
Return to: PBR Home | Drug Research | Drug Delivery

Teva launches generic Vytorin tablets in US

Published 27 April 2017

Teva Pharmaceutical Industries has launched the generic Vytorin (ezetimibe and simvastatin) tablets in the US.

Ezetimibe and simvastatin tablets are a prescription medicine that contains two cholesterol lowering medicines, ezetimibe and simvastatin, which are used along with diet to:

  • Lower the level of “bad” cholesterol (low density lipoprotein cholesterol or LDL)
  • Increase the level of “good” cholesterol (high density lipoprotein cholesterol or HDL)
  • Lower the level of fat in blood (triglycerides)

Ezetimibe and simvastatin tablets further enhance Teva’s statin portfolio. With nearly 600 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S.

Currently, one in six generic prescriptions dispensed in the U.S. is filled with a Teva product.

Vytorin had annual sales of approximately $678 million in the U.S. according to IMS data as of February 2017.



Source: Company Press Release